产品
编 号：F745459
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1471999-69-5
产品详情
生物活性：
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer.
体内研究：
Depatuxizumab (10， 40 mg/kg， i.p.， 每周3次， 持续2周) 在 Nu/Nu 小鼠的 U87MGde2-7 多形性胶质母细胞瘤 (GBM) 模型和 A431 鳞状荷瘤模型中显著抑制肿瘤生长。Depatuxizumab (10， 40 mg/kg， i.p.， 每周3次， 持续2周) 在 NSG 小鼠的 EGFRvIII 阳性 GBM-SN0199-PDX 模型中抑制肿瘤生长和 pEGFR 水平。Depatuxizumab (2-40 mg/kg， i.p.， 每周三次， 持续2周) 在 SCID Beige 小鼠的 SCC15 荷瘤模型中以剂量依赖方式抑制肿瘤生长。Animal Model:U87MGde2-7 glioblastoma multiforme (GBM) model of Nu/Nu mice
Dosage:10, 40 mg/kg, three times a week for 2 weeks
Administration:Intraperitoneal injection (i.p.)
Result:Inhibited tumor growth significantly more than Cetuximab (HY-P9905).Promoted a significant increase in TGI (tumor growth inhibition) when it combined with Temozolomide (HY-17364).
Animal Model:EGFRvIII-positive GBM SN0199 PDX model, 3 to 5 mm3 passage 3 (P3) tumor fragments were s.c. trochar implanted in the right rear flank of NSG mice
Dosage:10, 40 mg/kg, three times a week for 2 weeks
Administration:Intraperitoneal injection (i.p.)
Result:Inhibited tumor growth significantly and reduced levels of pEGFR.
Animal Model:A431 squamous xenograft model of Nu/Nu mice
Dosage:10, 40 mg/kg, three times a week for 2 weeks
Administration:Intraperitoneal injection (i.p.)
Result: Inhibited tumor growth with comparable activity to Cetuximab (HY-P9905) dosed in an equivalent manner at 10 mg/kg. Inhibited tumor growth by 58% at 40 mg/kg.
Animal Model:SCC15 xenograft model of SCID Beige mice
Dosage:2, 10, 20, 40 mg/kg, three times a week for 2 weeks
Administration:Intraperitoneal injection (i.p.)
Result:Inhibited tumor growth with dose manner.Reduced the level of pEGFR and total EGFR in time-dependent.Reduced cell proliferation as measured by phospho-histone H3.Increased apoptosis as measured by caspase-3 cleavage.Increased antitumor activity when it was combined with both Cisplatin(HY-17394) or/and 5-FU(HY-90006) at 10 mg/kg.
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer.
体内研究：
Depatuxizumab (10， 40 mg/kg， i.p.， 每周3次， 持续2周) 在 Nu/Nu 小鼠的 U87MGde2-7 多形性胶质母细胞瘤 (GBM) 模型和 A431 鳞状荷瘤模型中显著抑制肿瘤生长。Depatuxizumab (10， 40 mg/kg， i.p.， 每周3次， 持续2周) 在 NSG 小鼠的 EGFRvIII 阳性 GBM-SN0199-PDX 模型中抑制肿瘤生长和 pEGFR 水平。Depatuxizumab (2-40 mg/kg， i.p.， 每周三次， 持续2周) 在 SCID Beige 小鼠的 SCC15 荷瘤模型中以剂量依赖方式抑制肿瘤生长。Animal Model:U87MGde2-7 glioblastoma multiforme (GBM) model of Nu/Nu mice
Dosage:10, 40 mg/kg, three times a week for 2 weeks
Administration:Intraperitoneal injection (i.p.)
Result:Inhibited tumor growth significantly more than Cetuximab (HY-P9905).Promoted a significant increase in TGI (tumor growth inhibition) when it combined with Temozolomide (HY-17364).
Animal Model:EGFRvIII-positive GBM SN0199 PDX model, 3 to 5 mm3 passage 3 (P3) tumor fragments were s.c. trochar implanted in the right rear flank of NSG mice
Dosage:10, 40 mg/kg, three times a week for 2 weeks
Administration:Intraperitoneal injection (i.p.)
Result:Inhibited tumor growth significantly and reduced levels of pEGFR.
Animal Model:A431 squamous xenograft model of Nu/Nu mice
Dosage:10, 40 mg/kg, three times a week for 2 weeks
Administration:Intraperitoneal injection (i.p.)
Result: Inhibited tumor growth with comparable activity to Cetuximab (HY-P9905) dosed in an equivalent manner at 10 mg/kg. Inhibited tumor growth by 58% at 40 mg/kg.
Animal Model:SCC15 xenograft model of SCID Beige mice
Dosage:2, 10, 20, 40 mg/kg, three times a week for 2 weeks
Administration:Intraperitoneal injection (i.p.)
Result:Inhibited tumor growth with dose manner.Reduced the level of pEGFR and total EGFR in time-dependent.Reduced cell proliferation as measured by phospho-histone H3.Increased apoptosis as measured by caspase-3 cleavage.Increased antitumor activity when it was combined with both Cisplatin(HY-17394) or/and 5-FU(HY-90006) at 10 mg/kg.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备